The Summary
In this double-blind, randomized controlled trial, researchers evaluated whether daily low-dose lithium could slow cognitive decline in 80 older adults (aged 60+) with mild cognitive impairment (MCI). Over a two-year period, participants received either lithium or a placebo. Although none of the six primary outcomes (including brain volume and overall cognitive measures) met strict statistical significance, the lithium group showed a slower rate of verbal memory decline compared to the placebo group. This pilot study demonstrated that low-dose lithium is feasible and generally safe, paving the way for larger clinical trials.
Why this is interesting
Lithium is widely known as a high-dose psychiatric drug, but scientists have long suspected that trace amounts might protect brain cells. This is the first randomized trial to test this theory in people with mild cognitive impairment. While not a definitive cure, the finding that lithium-treated individuals experienced about half the rate of verbal memory decline is highly encouraging. For readers, it suggests that very low, safer doses of lithium may eventually become a viable strategy to preserve memory as we age, though larger studies are still needed to confirm these protective benefits.